positron emission tomography (pet) is a sensitive and noninvasive imaging method that is widely used to explore molecular events in living subjects. pet can precisely and quantitatively evaluate cellular apoptosis, which has a crucial role in various physiological and pathological processes. In this protocol, we describe the design and use of an engineered cyclic herpes simplex virus 1-thymidine kinase (HsV1-tK) pet reporter whose kinase activity is specifically switched on by apoptosis. the expression of cyclic tK (ctK) in healthy cells leads to inactive product, whereas the activation of apoptosis through the caspase-3 pathway cleaves ctK, thus restoring its activity and enabling pet imaging. In addition to detailing the design and construction of the ctK plasmid in this protocol, we include assays for evaluating the function and specificity of the ctK reporter in apoptotic cells, such as assays for measuring the cell uptake of pet tracer in apoptotic cells, correlating doxorubicin (Dox)-induced cell apoptosis to ctK function recovery, and in vivo pet imaging of cancer cell apoptosis, and we also include corresponding data acquisition methods. the time to build the entire ctK reporter is ~2-3 weeks. the selection of a stable cancer cell line takes ~4-6 weeks. the time to implement assays regarding ctK function in apoptotic cells and the in vivo imaging varies depending on the experiment. the cyclization strategy described in this protocol can also be adapted to create other reporter systems for broad biomedical applications.
IntroDuctIon
Conventional imaging modalities, such as computed tomography (CT), are primarily used to obtain anatomical information, whereas molecular imaging is used to study biological events at the cellular and subcellular levels, revealing complicated biological cascades and enabling early detection of diseases and therapy response monitoring 1 . PET is a powerful molecular imaging tool that can be used to noninvasively and sensitively monitor cellular and molecular events that occur in the progression of diseases such as cancer 2 . Using a radioisotope-labeled target-specific tracer, which has unlimited signal penetration within organs and tissues, PET provides sufficient spatial and temporal resolution for exploring biological events in animal models and humans 3 . In this protocol, we describe the design and use of a PET reporter system to monitor apoptosis; however, this reporter system can be adapted using a similar rationale to monitor alternative enzyme activities.
Imaging-based methods to monitor apoptosis
Programmed cell death, or apoptosis, is an important cellular event that is involved in biological development and many pathological processes 4 . For effective anticancer therapy, most chemotherapeutic agents induce cancer cell death, primarily via apoptosis. In drug discovery and development, chemical compounds are usually screened for their ability to target specific cytosolic proteins or enzymes at different apoptotic stages (either to enhance or to inhibit activity). However, endogenous mutations of cancer cells counteract the apoptosis-induction effect of chemotherapeutics, which leads to unwanted drug resistance in anticancer therapy 5, 6 . It is thus highly important to develop sensitive molecular imaging methods to evaluate apoptosis during anticancer treatment in order to monitor therapy response from an early stage and to improve the medical management of patients 7 . In addition, the development of imaging probes for monitoring the progression of apoptosis in living organisms enables a better understanding of the complicated pathological changes that occur during treatment.
Several imaging strategies have been developed to noninvasively monitor apoptosis, 8, 9 . One strategy is the measurement of phosphatidylserine accumulation on apoptotic cell membranes via its binding affinity with annexin V, which is either labeled with isotopes for radionuclide imaging or conjugated with fluorophores for optical imaging [10] [11] [12] . An alternative approach is to use a radionuclide-labeled small molecule, ML10, which binds to the surface of apoptotic cells for PET imaging 13 . However, it can be difficult to distinguish apoptosis from necrosis using cell surface markers, as necrotic and apoptotic cells usually share identical surface characters 14 . To circumvent this problem, the imaging of specific intracellular apoptotic mediators can be used to study intracellular activities during apoptosis, especially in the early stages of this process.
The cytosolic caspases, a family of cysteine proteinases, have essential roles in apoptosis 15, 16 . Caspase-3, the 'executioner' of apoptosis, is a highly potent target molecule for apoptosis imaging 17, 18 . Various activatable probes have been developed to monitor caspase-3 activity under microenvironmental cues in vivo [19] [20] [21] [22] . However, most probes are associated with high background noise owing to nonspecific cleavage 23 and low cell membrane permeability. Genetically coded fluorescent or bioluminescent reporter systems have also been constructed to detect caspase-3 activities 24 . These reporter systems have become valuable tools to investigate spatiotemporal caspase activities in living cells 25 or animals 26 . However, optical reporter systems are limited by photon penetration attenuation and lack of quantitative and tomographic outputs. It is thus highly desirable to develop a sensitive, quantitative and translational reporter system for real-time apoptosis imaging.
Design of a functional cyclic HSV1-TK reporter and its application to PET imaging of apoptosis
HSV1-TK (encoded by the HSV1-TK gene), along with its radiolabeled specific substrates, is an enzyme-based reporter system that has been extensively used for PET imaging [27] [28] [29] . After phosphorylation by HSV1-TK, purine and pyrimidine nucleoside analogs become highly positively charged and accumulate in cells, allowing signal detection by single-photon emission computed tomography (SPECT) or PET 30 . Over the past decade, our laboratory has used an HSV1-TK PET reporter system for real-time tracking of embryonic stem cells after cardiac injection 31 , for tumor-targeted imaging of modified virus particles 29 and for the evaluation of new PET tracers 32, 33 .
Recently, we have developed and used a genetically encoded functional HSV1-TK in truncated and cyclic form for sensitive PET imaging of caspase-3 activities during apoptosis 34 . The major applications of this cTK are preclinical screening of potential apoptosis inducers or inhibitors in living animals and real-time monitoring of cell apoptosis in a noninvasive and quantitative manner by PET. By changing the substrate recognition sites in cTK structure, this cTK-based PET imaging platform can be used to detect the activities of other cellular enzymes, such as cathepsin B, in real time. The cTK system can also be combined with other engineered enzyme systems, such as cre-loxP 35 , for inducible reporter gene expression or clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) (CRISPR/Cas9) 36, 37 , enabling sensitive functional PET imaging in transgenic mice 38, 39 .
Here we describe the design and development of cTK and an application in PET imaging of Dox-induced apoptosis in cancer cells (in vitro and in vivo). This cTK reporter system can be combined with other imaging modalities or artificial enzyme systems to broaden its range of applications.
Experimental design
This protocol describes the rationale and experimental procedures for the construction of the cTK plasmid (Steps 1-29), synthesis of 18 F-FHBG tracer (Steps [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] as the functional TK substrate, verification of cTK function in apoptotic cells and the use of it for in vivo PET imaging of tumor apoptosis (Step 43A-43C). The successful construction of the cTK plasmid is the major task in this protocol. Adapting the following rationale should enable the development of cyclic reporters to detect other enzyme activities; however, it is important to bear in mind that not all enzymes are suitable for cyclization. One should screen the specific enzyme sequences and test the function recovery rate when using the described cyclization strategy to check suitability. All the subsequent procedures are used to serve and validate the function and application of the cTK plasmid. The success of this protocol is based on the integration of molecular biology, PET radiochemistry and small-animal imaging.
cTK reporter construct design Figure 1 illustrates the principle of cyclic TK reporter design and preselected permutation sites for effective PET imaging. The two fragments of DnaE intein (split DnaE as DnaEc and DnaEn; PCC6803; ref. 40 ) are fused to the flank ends of HSV1-TK (TK) connected by a caspase-3 recognition substrate sequence, Asp-Glu-Val-Asp (DEVD), on the N and C termini of the TK sequence. Upon translation into a single polypeptide in the cytosol, the split fragments of TK undergo ligation through intein protein splicing, resulting in a closed circular polypeptide. We initially engineered the whole HSV1-TK sequence into a truncated version by deleting the first 45 amino acids, which showed reduced cytotoxicity in comparison with the full-length TK 41 . More importantly, the truncation reduces the structurally flexible region of the entire TK structure that restrains the tension of cyclic protein structure, prohibiting the accessibility of catalytic center to its substrates. A PEST sequence, a peptide sequence rich in proline (P), glutamic acid (E), serine (S) and threonine (T), was introduced to the cTK structure to accelerate the degradation of the unspliced protein. Hence, only the cyclic form of TK was retained in the cytosol 42, 43 . Upon caspase-3 activation, the DEVD sequence was cleaved, and the linear form of cTK was released to restore TK activity to catalyze the phosphorylation of its tracer substrates trapped in cells for PET imaging 27 . To successfully develop the functional cTK, it was crucial to identify the specific sites on the primary TK polypeptide sequence, from which the TK sequence can be split into two fragments in the cTK construct. The wild TK is a homodimer with 376 residues per subunit displaying the general αβ folding pattern 44 (Fig. 1a) . The amino acid sequences from 161 to 192 serve as the substrate-binding domain. The amino acid at site 163 critically determines the enzymatic activity of TK, and site 162 is responsible for coordination with Mg 2+ . The amino acids at sites 317 and 318 are essential in TK homodimer formation. All the above sites on the TK sequence are not appropriate candidate positions for splitting. In addition, it has been reported that the mutation of valine at site 119 into cysteine (V 119 C) led to a higher K m value in ATP binding 45 . This sitedirected mutation was included in the construct, and this site was not chosen in protein fragmentation splitting design. On the basis of the analysis of protein crystal structure of TK, we identified three potential splitting sites to construct cTK. Among them, one (Asp 76 ) is within the catalytic domain of TK, and the other two sites (Ala 266 and Asn 276 ) are out of the catalytic active region, while functioning as connecting sequences in α-helixes (Fig. 1b) . Hence, the three identified molecularly engineered cTK reporters, designated as cTK76, cTK266 and cTK276, were constructed through linking the N and C termini of truncated TK with DEVD peptide, which is flanked by DnaE intein at each end (Fig. 1c) . The results from cell uptake experiments indicated that the Ala 266 is the optimal split site to form cyclic TK with relatively high tracer cell uptake and low background noise (Supplementary Fig. 1 ).
For the absolute radioactivity test (Fig. 2a) , cTK276 > cTK266 > cTK76, whereas cTK266 showed the most prominent radioactivity fold change after normalizing with control cells (Fig. 2b) . This comparison suggests that cTK276 may result in higher background noise for imaging, and cTK76 is not appropriate for imaging study. Among the three different split sites in cTK vector construction, we chose cTK266, which maintains good enzyme function after caspase-3 cleavage, and presents the lowest background noise in 18 F-FHBG uptake. Thus, all the procedures described in this protocol use the cTK266 reporter.
Animal model and cell line
It is strongly recommended that the selected cell line used in relevant studies go through drug-sensitivity testing before use in this assay. It is well known that cancer cells may present drug resistance to particular chemotherapeutic drugs by endogenous or exogenous routes 46 . The success of functional cTK in apoptosis PET imaging relies much on the high sensitivity of selected cancer cells to chemotherapeutic agents, which ultimately leads to significant apoptosis through caspase-3 signaling pathway activation [47] [48] [49] . In addition, some cancer cells, such as MCF-7 breast cancer cells, undergo caspase-3-independent apoptosis 50, and they are thus not appropriate for cTK PET imaging, whereas they can be used as the negative control cell line to confirm the cTK specificity in apoptosis. Moreover, it is highly recommended that cancer cells used in the relevant studies independently express another reporter system, such as firefly luciferase (fLuc) or renilla luciferase (RLuc), to serve as a cell proliferation indicator in vitro and in vivo. The signal from cTK PET imaging can be normalized to the signal generated from the additional reporter system for comparison.
Before in vivo imaging, an appropriate xenograft tumor model should be well established. The tumor volume should be well controlled to be 150-200 mm 3 (calculated as length × width 2 /2, ~7-8 mm in diameter). Larger tumor sizes may have necrosis inside the tumors, which may lead to high background noise or false positive signal. Small tumor sizes may have immature tumor-associated blood vessels and an undeveloped tumor microenvironment.
For the animal tumor model described in this protocol, it is strongly recommended to have six mice in each group to obtain statistically meaningful results. However, if one uses a different experimental model, such as a different cell line, transgenic mice and so on, the animal size number per group should be adjusted on the basis of pilot studies. •
MaterIals

REAGENTS
Box 1 | Generation of a cTK stable transgenic cell line • tIMInG 4-6 weeks
To facilitate the establishment of tumor xenograft in nude mice for PET imaging of apoptosis, a stable transgenic cell line should be first established. The UM-SCC-22B (or 22B) cell line was chosen because of its high sensitivity to Dox-induced apoptosis in our laboratory 34 (supplementary Fig. 2 ).
MaterIals
Human head and neck squamous carcinoma UM-SCC-22B cell line (University of Michigan)  crItIcal Other cell lines can be used if apoptosis can be induced.
proceDure Day 1: 1. Culture 1 × 10 6 22B cells in a 10-cm tissue culture dish in DMEM supplemented with 10% (vol/vol) FBS, 100 U/ml penicillin and 100 mg/ml streptomycin tissue culture medium. Prepare two cell culture dishes so that you can use one dish as a negative control for Zeocin selection.  crItIcal step The cultured cell density per dish is crucial for subsequent transfection efficiency. In a typical experiment, one should estimate the cell number to ensure 70-80% confluency on the day of transfection (day 2). Both high and low cell density can adversely affect transfection efficiency. It is strongly recommended that a cell growth curve is calculated before performing stable transfection. ? trouBlesHootInG 6. Most of the cells die over the selection period (1-2 weeks), whereas sporadic cell colonies become resistant to Zeocin owing to prior successful transfection. Pick up colonies into a six-well plate, one colony for each well, when colonies become large and visible. To pick up the colonies, warm up 0.25% (wt/vol) trypsin in a 37 °C water bath. Aspirate the medium and wash the cells with PBS two times. Withdraw 20 µl of trypsin solution using a yellow tip, and then apply it on cell colonies. Scrape each colony gently with the yellow tip and aspirate the colony into the yellow tip. Transfer the aspirated cells to one well of a six-well plate containing 1 ml of tissue culture medium with 100 µg/ml Zeocin.  crItIcal step Avoid picking up cells from close or overlapped colonies. Only pick up the cells in the central part of each colony. During the scraping and transferring operations, try to minimize the time cells are exposed to air. Long exposure to air without medium substantially lowers cell viability and could induce apoptosis. ? trouBlesHootInG 7. Continue to culture the cells in selection medium to confluence. Split the cells in each well into six single wells of a six-well plate.
? trouBlesHootInG 8. When the cells become confluent, freeze one well of cells, continue to expand one well of cells and test the third well of cells by real-time PCR to examine the cTK expression level, as described in the following steps.  crItIcal step The fLuc-expressing 22B cells can be selected by following the same procedure as that used in steps 1-8, but 500 µg/ml G418 instead of Zeocin should be used for selection. In doing fLuc selection, the bioluminescence test of selected cells is conducted by adding 10 µl of d-luciferin (33 mg/ml) to cultured cells in a 24-well plate. 9. Choose three colonies randomly to test the cTK expression level in stable selected cells. To run real-time PCR, lyse the cells with TRIzol reagent to isolate total RNA according to the manufacturer's instructions. Reverse-transcribe an equal amount of total RNA (1 ng) into cDNA using the First-Strand Synthesis kit according to the manufacturer's instruction. To run real-time PCR, amplify synthesized cDNAs using the power SYBR Green PCR master mix kit according to the manufacturer's instructions. Use GAPDH as the housekeeping gene. • •
proceDure plasmid construction round 1: cloning Dnaec cDna into pcDna3.1(+)/Zeo vector to produce Vectorr1 • tIMInG 3-4 d ! cautIon All chemical reactions should be carried out with caution in designated fume hoods. Most of the reagents in this protocol are toxic or harmful, and they require the use of lab goggles, gloves and a lab coat. In some conditions, a face mask will also be needed for protection. 1| Amplify the cDNA fragment of DnaEc by PCR using high-fidelity polymerase. Use the designated oligonucleotide primers shown in 
3|
Run the PCR product on a 0.8% (wt/vol) agarose gel in 1× TAE buffer to check the quality of cDNAs (should be a single band) and to check that the size is ~1.3 kbp.
4|
Digest the cDNA of DnaEc and pcDNA3.1/Zeo(+) (vector) by Hind III-HF and BamH I-HF (buffer 4, BSA) in 20 µl at 37 °C overnight. Purify the digested DnaEc cDNA using the Qiagen PCR purification kit according to the manufacturer's instructions.  crItIcal step NEB has changed its buffer names. In this protocol, we use the company's previous buffer name, buffer 4. Currently, the CutSmart buffer is used for all high-fidelity restriction enzyme reactions. In our experimental test, both buffers yielded identical DNA digestion products with the same ligation results.
5|
Mix the digested vector with the appropriate volume of 6× loading dye. Run the digested vector on a 1% (wt/vol) agarose gel with GelRed nucleic acid stain using TAE buffer. Set the voltage to 100 V for 30 min. Use a 1-kb DNA ladder as the marker. Cut the target liner vector (size 5 kbp) using a sharp scalpel under UV light. Minimize the size of the cut gel to include the linear plasmid only, but not smears. ! cautIon In this step, the investigator is subjected to intense UV exposure. Wear a UV-protective head shield, gloves and lab coat to cover all the skin exposed to UV irradiation. Dispose of the gel in an appropriate waste box.  crItIcal step Minimize the UV exposure time to prevent mutation of the DNA or unexpected damage. 
6|
9|
On the next day, pick up a single colony into 3 ml of LB medium with 100 µg/ml ampicillin in a 14-ml roundbottom tube, and culture it in the orbital shaker at 37 °C at 250 r.p.m. overnight. After overnight culturing, the LB medium should become cloudy with an optical density of ~0.6-0.8 as measured by a UV-visible spectrophotometer.
10|
Transfer the broth into 1.5-ml sterile microcentrifuge tubes, 1 ml per tube, and spin down the E. coli pellet using a benchtop centrifuge at 3,500g for 10 min at room temperature.  crItIcal step Avoid excessive centrifugation, as it may make the pellet difficult to resuspend.  pause poInt Cultured bacteria in LB medium can be stored at 4 °C for up to 2 weeks. Alternatively, bacteria in LB medium can be aliquotted into several 1.5-ml sterile microcentrifuge tubes and mixed with 30% (vol/vol) glycerol solution (autoclaved for sterilization) for long-term storage in a −80 °C freezer. 19| Perform double digestion of the cDNA fragment of purified TKn and VectorR2 by EcoRI and PstI-HF (buffer 4, BSA) enzymes in 20 µl at 37 °C overnight. Purify the digested TKc cDNA fragment using the Qiagen PCR purification kit according to the manufacturer's instructions.
11|
20|
Repeat Steps 4-11 to purify digested VectorR2, and then insert the cDNA fragment of TKn into VectorR2 plasmid to produce VectorR3. 23| Perform double digestion of the cDNA fragment of purified DnaEn and VectorR3 by NotI-HF and PstI-HF (buffer 4, BSA) enzymes in 20 µl at 37 °C overnight. Purify the digested cDNA fragment of DnaEn using the Qiagen PCR purification kit according to the manufacturer's instructions.
24|
Repeat Steps 4-11 to purify digested VectorR3, and then insert the cDNA fragment of DnaEn into VectorR3 plasmid to produce VectorR4. 27| Perform double digestion of the cDNA fragment of purified PEST and VectorR4 by NotI-HF and XhoI (buffer 4, BSA) enzymes in 20 µl at 37 °C overnight. Purify the digested PEST cDNA fragment using the Qiagen PCR purification kit according to the manufacturer's instructions.
28|
Repeat Steps 4-11 to purify the digested VectorR4, and insert the PEST cDNA fragment into VectorR4 plasmid to produce the complete cTK plasmid.
29|
Sequence the entire cTK plasmid to check the accuracy of cloning from round 1 to round 5.  pause poInt The cTK plasmid can be stored at −80 °C for long-term storage.
synthesis of the HsV1-tK substrate: 18 F-FHBG • tIMInG 1-1.5 h ! cautIon As radioactive chemicals will be used throughout this experiment, the personnel involved in this study should have received appropriate radiation safety training. Radioactive chemical waste should be handled strictly in accordance with the institutional radiation safety protocol.
30|
Add 60 µl of 0.1 M potassium carbonate and 100 µl of Kryptofix 222 (4.5 mg in ACN) in a 1-ml V-vial.
31|
Add ~3.7 GBq (100 mCi) of no-carrier-added aqueous H 18 F from the cyclotron target into the above mixed solution. ! cautIon High levels of radioactivity are used in this step. Handle radioactivity with extreme care. Wear radiation-protective devices.
32|
Remove the solvent under a stream of argon while heating it in a 105 °C hot block. Remove residual water by azeotropic drying with 100 µl of ACN three times (100 µl × 3).
33| Dissolve 1 vial (3 mg) of Tysol-FHBG into 100 µl of anhydrous DMF.
34|
Add the Tysol-FHBG dissolved in DMF into the anhydrous potassium fluoride/Kryptofix 222 complex.  crItIcal step The anhydrous condition of the reaction system is very important for labeling and final yield.
35| Vigorously vortex the mixture from
Step 34 and heat it at 160 °C for 15 min, followed by dilution with Milli-Q water (10 ml).
36| Equilibrate 100 mg of C-18 BondElut cartridge with 2 ml of ethanol and 4 ml of water before adding the above intermediate product into the cartridge.
37| Wash the cartridge with 2 ml of water, and elute the product from the cartridge with 20% (vol/vol) methanol in dichloromethane.
38|
Evaporate the organic solvent. Treat the residue with 200 µl of 1 N HCl in methanol and 200 µl of 1 N HCl in water and heat the mixture at 105 °C for 10 min.  crItIcal step The order in which the organic and aqueous phases are added into the residue can substantially affect the final product.
39|
Remove the bulk of the methanol under an argon stream at room temperature. ! cautIon Control the velocity of the argon stream to prevent splashing of chemicals.
40| Add 600 µl of 50 mM NH 4 OAc to the residue.
41| Apply the solution from
Step 48 to semipreparative HPLC for final product separation. Use a mobile phase of 7% (vol/vol) ethanol in 50 mM NH 4 OAc and a flow rate of 5 ml/min. The elution time of 18 F-FHBG is ~10-11 min (column Luna C18, 10 × 250 mm, Phenomenex). Measure the purity of eluted 18 F-FHBG by radio-HPLC; it should be >97%. After cTK plasmid construction and transfection into 22B cells, we recommend that a real-time PCR test be performed to screen for the cells expressing the highest cTK variant expression (as described in Box 1;
Step 9 of the PROCEDURE). These cells should subsequently be chosen for future in vivo PET imaging studies. Figure 2 shows the expression level of different cTK variants after transfection and real-time PCR test in 22B cells. We chose the highest expression cells for our further studies: cTK76(4), cTK266(1), cTK276(3). For ease of identification, cTK76 = cTK76(4), cTK266 = cTK266(1) and cTK276 = cTK276(3). (Fig. 3a,b) . In most cases, 5 µg/ml Dox was able to induce extensive cell apoptosis after 24 h of incubation. A longer incubation time (72 h) resulted in markedly low cell proliferation (Fig. 3c,d ).
In vitro characterization of the ctK266 reporter
In cTK266 stably transfected cTK-22B cells, the 18 F-FHBG uptake increment was proportional to Dox dosage (Fig. 4a) . Western blot analysis (Fig. 4b) showed increased concentration of linear TK protein with increased Dox dosages compared to untreated controls, whereas the concentration of cyclic TK protein decreased accordingly. Results from Figure 4 indicate that cell apoptosis condition can be monitored through 18 F-FHBG radiotracer, via cTK cleavage by caspase-3.
caspase-3 specificity of ctK266 function in ctK-22B cancer cells
The specificity of an imaging reporter is essential for precise molecular imaging. To evaluate the specificity of the cTK266 reporter in apoptosis imaging via the caspase-3 signaling pathway, we first used a caspase inhibitor, IDN6556, to study the 18 F-FHBG uptake. The result (Fig. 5a ) showed statistically significant (P < 0.01) 18 F-FHBG cell uptake inhibition in the presence of IDN6556. Next, we used anti-caspase-3 siRNA to downregulate caspase-3 in cTK-22B cells, followed by a 18 F-FHBG uptake study. Figure 5b showed gradually lowered 18 F-FHBG cell uptake with increasing concentrations of anticaspase-3 siRNA. To further confirm the caspase-3 specificity of the cTK266 reporter, we used a special cell line, MCF-7, whose apoptosis is naturally independent of the caspase-3 signaling pathway. Upon transfection of the caspase-3 plasmid followed by Dox treatment, there was a statistically higher 18 F-FHBG cell uptake than in all other control groups (Fig. 5c ). All the above assays solidly demonstrated high caspase-3 specificity of our cTK reporter, and they should be used to confirm the specificity of the reporters generated using this protocol.
In vivo pet scanning and BlI of apoptosis induced by Dox treatment
Dox treatment in a cTK-22B-fLuc stably transfected 22B cell xenograft tumor model can lead to extensive apoptosis in tumors. Figure 6a shows the PET imaging of apoptosis via cTK reporter after 18 F-FHBG administration (Fig. 6b) . Extensive PET signal was detected in the tumor after Dox treatment. In BLI imaging of the corresponding cell proliferation, Dox treatment led to a significantly lower cell proliferation than that seen in the untreated control, as indicated by low BLI signal (Fig. 6c,d) , which was consistent with PET imaging data showing extensive apoptosis after chemotherapeutic agent treatment. Dox treatment thus represents a suitable positive control when using this assay to look at alternative chemotherapeutic agents. 
